Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06315608 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MRG-001 in Patients With Amyotrophic Lateral Sclerosis

Name: MRG-001 in Patients With Amyotrophic Lateral Sclerosis — clinical trial record (NCT06315608)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusUnknown

PhasePhase 2

SponsorMedRegen LLC

Started2025-07-01

View on ClinicalTrials.gov ↗

Record status

This record was last updated August 23, 2024 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.

The proposed study is an Open-Label, Single-Dose Study to Assess the Safety, and Pharmacodynamics (PD) signals of MRG-001 in Patients with Amyotrophic Lateral Sclerosis (ALS). MRG-001 will be administered subcutaneously 3 times per week for 2 weeks. This cycle will be repeated for 3 months. In total, patients are expected to receive 18 injections over the span of 3 months.

Amendment history 1 change detected by DataLookout

2026-09-06

Trial status changed: Not Yet Recruiting → Unknown

Trial Details

NCT Number	NCT06315608
Lead Sponsor	MedRegen LLC
Conditions	Amyotrophic Lateral Sclerosis, Lou Gehrig Disease, Motor Neuron Disease, Motor Neuron Atrophy
Enrollment	10 participants
Start Date	2025-07-01
Primary Completion	2026-01-01 (estimated)
Study Completion	2026-03-01 (estimated)
Updated on ClinicalTrials.gov	2024-08-23